Damora Therapeutics, Inc. annual report, FY2020

Business Context and Reporting Period

Filing: Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed March 29, 2021. The source identifies the registrant as Galecto, Inc., not Damora Therapeutics, Inc.; this entity discrepancy should be verified.

Galecto is a clinical-stage biotechnology company developing small-molecule inhibitors of galectin-3 and LOXL2 for fibrotic diseases and cancer. It has no approved products and generated no product revenue.

  • GB0139: Inhaled galectin-3 inhibitor in a 450-patient Phase 2b idiopathic pulmonary fibrosis trial.
  • GB2064: Oral LOXL2 inhibitor planned for a Phase 2 myelofibrosis trial.
  • GB1211: Oral galectin-3 inhibitor planned for trials in non-small cell lung cancer and liver cirrhosis.

Financial Performance and Liquidity

Metric20202019Change
Product revenue$0$0No change
Research and development expense$24.6 million$19.7 millionUp 25%
Purchased in-process R&D$0$16.8 millionDown 100%
General and administrative expense$9.0 million$2.4 millionUp 269%
Total operating expenses$33.6 million$39.0 millionDown 14%
Net loss$34.8 million$36.5 millionLoss narrowed 5%
Net loss per share$7.62$161.82Not directly comparable because of recapitalization and share-count changes
Cash used in operating activities$38.2 million$19.3 millionUse increased $18.9 million
Cash and cash equivalents$163.6 million$11.3 millionUp $152.3 million

Operating margin and profitability ratios are not meaningful because the company had no revenue. The accumulated deficit was $104.4 million at December 31, 2020. Total liabilities were $6.1 million, consisting primarily of accounts payable, accrued expenses and operating lease liabilities; the filing does not identify material funded debt.

Financing cash flow was $187.4 million, including net proceeds of approximately $39.7 million from Series C preferred stock, $61.4 million from Series D preferred stock and $86.3 million from the November 2020 initial public offering. All outstanding convertible preferred stock converted into common stock upon the IPO. Management stated that cash and cash equivalents were expected to fund operations into 2024 under its current plan, but additional capital will be required to complete clinical development.

Material Changes Versus 2019

  • R&D expense increased by $4.9 million, primarily due to higher chemistry, manufacturing and controls costs, clinical consulting, and personnel costs.
  • G&A expense increased by $6.6 million because of IPO-related professional fees, public-company costs, personnel additions and legal expenses.
  • The 2019 $16.8 million in-process R&D charge related to the PharmAkea acquisition did not recur in 2020.
  • Operating cash use more than doubled, reflecting the company’s expanding development and public-company activities.
  • Cash strengthened materially following preferred-stock financings and the IPO, while common shares outstanding increased to 25.3 million from 0.3 million at year-end 2019.
  • The company began trading on Nasdaq under the symbol GLTO in October 2020.

Guidance, Outlook, Risks and Unusual Items

  • The company expects continuing significant losses, increasing R&D and G&A expenses, and no product revenue unless and until a candidate receives regulatory approval and is commercialized.
  • Management expected Phase 2b GB0139 topline results in the second half of 2022, a Phase 2 GB2064 trial to begin in the first half of 2021, and GB1211 trials to begin in mid-2021 or the second half of 2021.
  • As a post-period development disclosed in the filing, a data safety monitoring board recommended discontinuing GB0139 dosing in patients receiving nintedanib or pirfenidone and in the 10 mg dose group because of an imbalance in serious adverse events across study groups. No mortality imbalance was identified. The protocol amendment remained subject to regulatory feedback.
  • COVID-19 delayed GB0139 enrollment and the planned GB1211 and GB2064 trials and could continue to affect enrollment, trial sites, manufacturing, supply chains and regulatory activities.
  • The company has no commercial product, limited operating history and substantial dependence on the success of its three clinical programs. Clinical efficacy, safety, enrollment, regulatory approval, manufacturing and reimbursement remain uncertain.
  • Management disclosed a material weakness in internal control over financial reporting related to the financial close process, insufficient U.S. GAAP and SEC-reporting expertise, and oversight of third-party service providers. Remediation included hiring a CFO and controller and developing formal reporting procedures.
  • The company reported no material legal proceedings and no off-balance-sheet arrangements. Contractual lease obligations totaled approximately $1.0 million at year-end 2020.

Most Important Facts to Verify

  • Confirm whether the intended issuer is Galecto, Inc. or Damora Therapeutics, Inc.; the supplied filing is for Galecto.
  • Verify the final regulatory status, revised design, enrollment and safety results of the GB0139 Phase 2b trial.
  • Assess whether the stated cash runway into 2024 remains valid after changes in trial scope, enrollment, costs and financing needs.
  • Review the company’s audited financial statements and subsequent filings for any revisions to cash, operating losses, share count or internal-control conclusions.
  • Track initiation, enrollment and readouts for GB2064 and GB1211, including whether COVID-19 or regulatory requirements caused further delays.
  • Evaluate dilution risk from future equity offerings, stock options and other financing arrangements.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.